Evidence map›Paper›PMID 41458598›Full record

ArticleFrontiers in oncology2025

Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer.

Ning Zhang, Yu Liu, Xiaodan Zhang, Meng Xie, Ying Zhang, Keqin Hua

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ning Zhang *Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Yu Liu *Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Xiaodan ZhangDepartment of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Meng Xie *Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Ying Zhang *Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Keqin Hua *Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Epithelial ovarian cancer (EOC) has a dismal prognosis, and recent therapeutic advancements have been limited. The aim of our study was to clarify the role and mechanism of cetrorelix in EOC apoptosis and to evaluate the clinical relevance of GnRHR, AKT, and FOXO1 in EOC patients. Methods: Apoptosis was assessed using flow cytometry, Hoechst staining, and Western blotting. FOXO1, p-AKT and GnRHR knockdown via siRNA was performed to reverse cetrorelix-induced apoptosis. Mechanistic insights were explored using apoptosis gene PCR arrays, qRT-PCR, and Western blotting. Results: Cetrorelix facilitated EOC apoptosis both Conclusion: These findings suggest that cetrorelix may induce EOC apoptosis via the PI3K/AKT-FOXO1 pathway, which provides mechanistic support for the therapeutic potential of GnRH antagonists in EOC management. Moreover, the identified critical regulatory pathways are prospective therapeutic targets for EOC management.

Indexed as

apoptosiscetrorelixepithelial ovarian cancergonadotropin-releasing hormone antagonistPI3K–AKT–FOXO1 pathway

Identifiers

PMID41458598
PMCPMC12740856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.